Bristol Defends Biomarker Strategy At ASCO, Expects Broad Label In Lung
Executive Summary
In the CheckMate 057 non-squamous NSCLC study, patients with low expression of PD-L1 taking Opdivo did not have better overall survival or response rates compared to docetaxel, but the duration of response was long and the PD-1 inhibitor has a far better safety profile.
You may also be interested in...
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.